Compound News and Research

RSS

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.

From QIAGEN Manchester Limited 15 Jul 2013

Patients with early AD also have undiagnosed pre-diabetes, says Georgetown neurologist

When Georgetown University neurologist R. Scott Turner, MD, PhD, began enrolling people with mild to moderate Alzheimer's disease into a nationwide study last year, he expected to find only a handful of participants with undiagnosed glucose intolerance, as all the patients were already under a doctor's care and those with known diabetes were excluded.

15 Jul 2013

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

12 Jul 2013

Research: Experimental drug can protect kidneys from acute kidney injury

New research reveals the mechanism by which an experimental drug can protect the kidneys from sudden damage, called acute kidney injury (AKI). The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), show how the drug may be able to save many lives and cut medical costs related to the condition.

12 Jul 2013

Scientists discover bacterium that stores biodegradable plastic

In Bolivia, in the largest continuous salt desert in the world, researchers from the Polytechnic University of Catalonia have found a bacterium that stores large amounts of PHB, a prized polymer. This biodegradable plastic is used by the food and pharmaceutical industries, for example to produce nanospheres to transport antibiotics.

11 Jul 2013

Researchers discover new class of antimalarial compounds

Despite renewed global efforts for eradication, malaria continues to exert devastating effects on human health. An estimated 220 million people are infected each year by malaria-causing Plasmodium parasites, which are transmitted by the bite of an infected mosquito. This enormous infection burden leads to some 660,000 lives lost to malaria each year, the majority of these young children in sub-Saharan Africa. While a vaccine to prevent malaria remains elusive, we depend on antimalarial compounds both to treat infections and prevent disease.

10 Jul 2013

Researcher uncover biomarkers from stem cells derived from bone marrow of ALS patients

Amyotrophic Lateral Sclerosis (ALS) is a devastating motor neuron disease that rapidly atrophies the muscles, leading to complete paralysis. Despite its high profile - established when it afflicted the New York Yankees' Lou Gehrig - ALS remains a disease that scientists are unable to predict, prevent, or cure.

10 Jul 2013

Research shows hydrogen sulfide is a key player in colon cancer metabolism

University of Texas Medical Branch at Galveston researchers have discovered that hydrogen sulfide - the pungent-smelling gas produced by rotten eggs - is a key player in colon cancer metabolism, and a potential target for therapies for the disease.

9 Jul 2013

Anti-cancer compounds offer hope for treating breast cancer

Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer.

9 Jul 2013

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children.

8 Jul 2013

Researchers produce potential antibiotic that targets bacterial enzyme critical to metabolic processes

University of Adelaide research has produced a potential new antibiotic which could help in the battle against bacterial resistance to antibiotics.

4 Jul 2013

Researchers identify two promising candidates for development of drugs to combat adenovirus

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have identified two promising candidates for the development of drugs against human adenovirus, a cause of ailments ranging from colds to gastrointestinal disorders to pink eye.

3 Jul 2013

FDA-approved formoterol drug improves cognitive function in mouse model of Down syndrome

An existing FDA-approved drug improves cognitive function in a mouse model of Down syndrome, according to a new study by researchers at the Stanford University School of Medicine.

3 Jul 2013

UVA researchers identify promising target for treating glioblastoma

Researchers at the University of Virginia Cancer Center have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts to develop effective treatments for this deadliest of cancers.

2 Jul 2013

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.

2 Jul 2013

Increased expression of Scara1 protein might impede progression of Alzheimer's disease: Study

Identification of a protein that appears to play an important role in the immune system's removal of amyloid beta (A-beta) protein from the brain could lead to a new treatment strategy for Alzheimer's disease. The report from researchers at Massachusetts General Hospital (MGH) has been published online in Nature Communications.

2 Jul 2013

Decorin protein in blood inhibits tumor progression, say researchers

Researchers from Thomas Jefferson University's Kimmel Cancer Center have discovered that decorin, a naturally occurring protein that circulates in the blood, acts as a potent inhibitor of tumor growth modulating the tumor microenvironment.

28 Jun 2013

Use of antibacterial soaps containing chemical triclocarban may harm nursing babies

A mother's prolonged use of antibacterial soaps containing the chemical triclocarban may harm nursing babies, according to a recent study from the University of Tennessee, Knoxville.

28 Jun 2013

Mouse models demonstrate new potential target in fight against Alzheimer's disease

Building on research published eight years ago in the journal Chemistry and Biology, Kenneth S. Kosik, Harriman Professor in Neuroscience and co-director of the Neuroscience Research Institute (NRI) at UC Santa Barbara, and his team have now applied their findings to two distinct, well-known mouse models, demonstrating a new potential target in the fight against Alzheimer's and other neurodegenerative diseases.

27 Jun 2013

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.

27 Jun 2013

Compound News and Research

FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients

Patients with early AD also have undiagnosed pre-diabetes, says Georgetown neurologist

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

Research: Experimental drug can protect kidneys from acute kidney injury

Scientists discover bacterium that stores biodegradable plastic

Researchers discover new class of antimalarial compounds

Researcher uncover biomarkers from stem cells derived from bone marrow of ALS patients

Research shows hydrogen sulfide is a key player in colon cancer metabolism

Anti-cancer compounds offer hope for treating breast cancer

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Researchers produce potential antibiotic that targets bacterial enzyme critical to metabolic processes

Researchers identify two promising candidates for development of drugs to combat adenovirus

FDA-approved formoterol drug improves cognitive function in mouse model of Down syndrome

UVA researchers identify promising target for treating glioblastoma

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Increased expression of Scara1 protein might impede progression of Alzheimer's disease: Study

Decorin protein in blood inhibits tumor progression, say researchers

Use of antibacterial soaps containing chemical triclocarban may harm nursing babies

Mouse models demonstrate new potential target in fight against Alzheimer's disease

FX006 demonstrates pain relief in Phase 2b osteoarthritis study, Flexion reports

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News